Boston Partners Acquires 40,153 Shares of ICON PLC (NASDAQ:ICLR)
Boston Partners raised its position in shares of ICON PLC (NASDAQ:ICLR) by 3.4% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 1,208,640 shares of the medical research company’s stock after buying an additional 40,153 shares during the period. Boston Partners’ holdings in ICON PLC were worth $118,193,000 as of its most recent filing with the SEC.
Several other institutional investors have also made changes to their positions in the stock. Shine Investment Advisory Services Inc. acquired a new position in shares of ICON PLC during the second quarter worth about $103,000. Huntington National Bank boosted its position in shares of ICON PLC by 5.0% in the second quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock worth $159,000 after buying an additional 77 shares in the last quarter. US Bancorp DE boosted its position in shares of ICON PLC by 15.0% in the first quarter. US Bancorp DE now owns 1,929 shares of the medical research company’s stock worth $154,000 after buying an additional 251 shares in the last quarter. Quantbot Technologies LP boosted its position in shares of ICON PLC by 40.9% in the first quarter. Quantbot Technologies LP now owns 2,022 shares of the medical research company’s stock worth $161,000 after buying an additional 587 shares in the last quarter. Finally, IFP Advisors Inc boosted its position in shares of ICON PLC by 2.7% in the first quarter. IFP Advisors Inc now owns 2,232 shares of the medical research company’s stock worth $178,000 after buying an additional 59 shares in the last quarter. Institutional investors own 92.55% of the company’s stock.
Shares of ICON PLC (NASDAQ:ICLR) opened at 101.40 on Friday. The company’s 50 day moving average is $100.50 and its 200-day moving average is $89.05. The firm has a market cap of $5.48 billion, a PE ratio of 20.57 and a beta of 0.60. ICON PLC has a 12 month low of $73.76 and a 12 month high of $109.32.
ICON PLC (NASDAQ:ICLR) last posted its quarterly earnings data on Thursday, July 27th. The medical research company reported $1.31 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.01. ICON PLC had a net margin of 15.97% and a return on equity of 28.72%. The business had revenue of $431 million during the quarter, compared to analysts’ expectations of $430.68 million. During the same quarter in the prior year, the business posted $1.14 earnings per share. ICON PLC’s revenue was up 5.0% compared to the same quarter last year. Equities research analysts predict that ICON PLC will post $5.32 EPS for the current year.
A number of brokerages have recently issued reports on ICLR. SunTrust Banks, Inc. upgraded shares of ICON PLC from a “hold” rating to a “buy” rating and increased their price objective for the company from $93.00 to $126.00 in a research note on Monday, July 31st. KeyCorp restated an “overweight” rating on shares of ICON PLC in a research note on Monday, July 31st. Mizuho increased their target price on shares of ICON PLC from $104.00 to $108.00 and gave the stock a “neutral” rating in a research report on Thursday, July 27th. Jefferies Group LLC reiterated a “buy” rating on shares of ICON PLC in a research report on Sunday, July 30th. Finally, ValuEngine cut shares of ICON PLC from a “buy” rating to a “hold” rating in a research report on Wednesday, May 31st. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. ICON PLC currently has a consensus rating of “Buy” and a consensus target price of $108.38.
ICON PLC Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICON PLC (NASDAQ:ICLR).
Receive News & Ratings for ICON PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.